Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
Immunostaining showed that the colon cancer was positive for CDX2, SATB2, had a loss of PMS2 and intact expression of MLH1, MSH2 and MSH6, negative for AMACR, while the prostate cancer was positive for AMACR, had intact expression of PMS2, MLH1, MSH2 and MSH6, and negative for CDX2 and SATB2.
|
30061258 |
2018 |
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
However, no study has comprehensively examined the relationship between CDX2 expression in colon cancer and clinical, pathologic, prognostic, and molecular features, including microsatellite instability and CpG island methylator phenotype (CIMP).
|
19584150 |
2009 |
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results suggest that pLVX-5HRE-hTERTp-CDX2-3FLAG gene therapy may be a promising novel approach to treat colon cancer.
|
28627695 |
2017 |
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
The expression of biomarkers CK20 and CDX2 for colon cancer were determined by immunocytochemistry assay.
|
30214379 |
2018 |
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
The homeoprotein encoded by the intestinal-specific Cdx2 gene is a major regulator of gut development and homeostasis, also involved in colon cancer as well as in intestinal-type metaplasias when it is abnormally expressed outside the gut.
|
25663763 |
2015 |
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Up to approximately 75% of low-CDX2 human colon cancer lesions show reduced levels of p27Kip1, whereas approximately 68% of high-CDX2 lesions retain expression of p27Kip1.
|
21224344 |
2011 |
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Loss of Cdx2 expression in colon cancer cells might reduce expression of Mucdhl and thereby lead to tumor formation.
|
22202456 |
2012 |
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Here, we show that lack of CDX2 expression is only present in the mesenchymal subgroup (CMS4) and in MSI-immune tumors (CMS1) and not in CMS2 and CMS3 colon cancer.
|
28328000 |
2017 |
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
We showed that various forms of Cdx2 coexist in the intestine and colon cancer cell lines, some of them being phosphorylated forms.
|
16027724 |
2005 |
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Downregulation of the colon tumour-suppressor homeobox gene Cdx-2 by oncogenic ras Constitutive activation of the ras proto-oncogene is a frequent and early event in colon cancers, but the downstream nuclear targets are not fully understood.
|
9926923 |
1999 |
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
SATB2 and CDX2 are prognostic biomarkers in DNA mismatch repair protein deficient colon cancer.
|
30962505 |
2019 |
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Real-time PCR and western blotting demonstrated that CDX2 expression was decreased by CoCl2 (100 microM) in both SW480 and LS174T cells. mRNA and protein expression of HIF-1alpha and mRNA expression of Snail was increased by hypoxia in both colon cancer cell lines.
|
20514449 |
2010 |
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, CDX2 was found to co-immunoprecipitate with the p65 subunit of NF-kappaB and to inhibit p65-induced NF-kappaB minimal promoter activity in colon cancer cells.
|
15013430 |
2004 |
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
Immunoprofiling of the specimens revealed a rare phenotype: the jejunal cancer was positive for cytokeratin (CK) 7, partially positive for CK20, and Cdx-2-negative, whereas the colon cancer was CK7(+), CK20(-), and Cdx-2(-).
|
19923997 |
2010 |
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
Moreover, this is the first report establishing CDX2 as transactivator of tumor growth-promoting gene expression in colon cancer, adding to untangle the complex and conflicting biological functions of CDX2 in colon cancer and supporting MS4A12 as important factor for normal colonic development as well as for the biology and treatment of colon cancer.
|
19781065 |
2009 |
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We found that the colon cancer cell lines HCT-116 and HCT-15 exhibited a confluence-dependent increase in CD26 mRNA and protein, associated with decreased expression of c-Myc, increased USF-1 and Cdx 2 levels, and unchanged HNF-1α expression.
|
21284881 |
2011 |
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
Immunohistochemical studies showed that the liver tumor and primary colon cancer were negative for cytokeratin (CK) 7 and positive for CK20 and Caudal-type homeobox transcription factor 2 (CDX-2).
|
30658608 |
2019 |
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We also show that HNF4<i>α</i> and CDX2 are required for the expression of these UGT genes in colon cancer cell lines, and show robust correlation of UGT expression with CDX2 and HNF4<i>α</i> levels in normal human colon.
|
29519853 |
2018 |
Malignant tumor of colon
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Haplotype analyses showed significant increased colon cancer risk for carriers of the Cdx-2-FokI A-T haplotype and the FokI-TaqI T-G haplotype.
|
18628249 |
2008 |
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The transcriptional regulation of the VTI1A-TCF4 fusion gene was investigated in LS174T cells where the activity of the VTI1A promoter was compared to that of the TCF7L2 promoter, and the transcription factor CDX2 was analyzed for gene regulatory activity of the VTI1A promoter through luciferase reporter gene assay using colon cancer cell lines as a model.
|
29975781 |
2018 |
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
However, consistent with a role for dominant repression mechanisms in CDX2 silencing, all somatic cell hybrids resulting from pairwise fusions between colon cancer lines with intact CDX2 expression and lines lacking CDX2 had reduced CDX2 transcripts and protein.
|
12947088 |
2003 |
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In order to elucidate further the molecular mechanisms underlying this phenomenon, we first hypothesized that Cdx1 or Cdx2 expression reduces colon cancer cell proliferation by inhibiting beta-catenin/T-cell factor (TCF) transcriptional activity.
|
15215241 |
2004 |
Malignant tumor of colon
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
To investigate whether NaB regulates expression of the Cdx2 gene in colon cancer cell lines.
|
11889074 |
2002 |
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
In the validation data set, which included 314 patients, the rate of 5-year disease-free survival was lower among the 38 patients (12.1%) with CDX2 protein-negative colon cancers than among the 276 (87.9%) with CDX2 protein-positive colon cancers (hazard ratio, 2.42; 95% CI, 1.36 to 4.29; P=0.003).
|
26789870 |
2016 |
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
To understand the functional contributions of CDX2 to colon cancer, we disrupted CDX2 in LOVO and SW48 human colon cancer cell lines by targeted homologous recombination.
|
16314840 |
2006 |